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Inflammatory bowel disease (IBD) encompasses various pathological conditions similar
but distinct that share a multifactorial etiology, including involvement of the intestinal
barrier function, the immune system, and intestinal microorganisms. Hsp60 is a
chaperonin component of the chaperoning system, present in all cells and tissues,
including the intestine. It plays important roles in cell physiology outside and inside
mitochondria, its canonical place of residence. However, Hsp60 can also be pathogenic
in many conditions, the Hsp60 chaperonopathies, possibly including IBD. The various
clinico-pathological types of IBD have a complicated mix of causative factors, among
which Hsp60 can be considered a putatively important driver of events and could play
an etiopathogenic role. This possibility is discussed in this review. We also indicate that
Hsp60 can be a biomarker useful in disease diagnosing and monitoring and, if found
active in pathogenesis, should become a target for developing new therapies. The
latter are particularly needed to alleviate patient suffering and to prevent complications,
including colon cancer.
Keywords: intestinal wall, microbiota, Hsp60, immune system, chaperoning system, inflammatory bowel disease,
chaperonopathy, chaperonotherapy
THE BOWEL AND ITS INFLAMMATORY DISEASES: A BRIEF
OVERVIEW
The intestinal tube is one of the first anatomical structures to form in the embryo, because of
the immediate nutritional needs of embryonic cells, and from the intestinal tube other structures
originate, such as exocrine and endocrine glands, airways, etc. (Chin et al., 2017). At the end of
organogenesis, the intestinal wall is composed of multiple layers, classically described, from the
inside, i.e., the lumen, to the outside, as mucosa, submucosa, muscularis propria and adventitia
(or serosa, when the peritoneum is present). However, this description does not take into account
the fact that, in living subjects, the most internal lining of the intestinal lumen consists of the
mucus. This is produced by epithelial cells of the mucosa and contains about 100 billion microbial
cells encompassing more than 10,000 different species, collectively called the intestinal microbiota.
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For this reason, we consider the most internal lining
of the intestinal wall in the living organism to be the
mucous-microbiota layer. We propose to name this layer
“MuMi layer” on account of its two major components, namely
the mucous and the microbiota, (Figure 1A). This functional
layer has a loose (as compared with the other intestinal layers)
and changeable structure mostly provided by the biofilms formed
by bacteria, archaea, and micro-eukaryotes that constitute the
microbiota. However, this layer is not visible under routine
histologic examination; it is lost during the processing of the
tissue for microscope observation due to the solubility of the
mucous in alcoholic solutions. Consequently, this internal lining
is systematically missed in histological studies and has, generally,
been ignored or forgotten despite its key role in intestinal
physiology and pathology.
The intestinal tube establishes multiple relationships with
other anatomical districts both through visceral innervation
and microvesicular trafficking. Examples of microvesicles are
exosomes and outer membrane vesicles produced, respectively,
by human and microbial cells. These vesicles can reach
through the bloodstream virtually any anatomical districts,
including some “protected sanctuaries” such as the brain,
testicles, and thymus (Yáñez-Mó et al., 2015). In addition,
intestinal mucosa cells produce and release soluble factors with
autocrine- and paracrine-like properties with some reaching
the general circulation and having systemic effects. This
complex homeostasis is subverted in some intestinal pathological
disorders, for example in inflammatory bowel disease (IBD).
Inflammatory bowel disease comprises chronic inflammatory
pathologies of the intestinal tract, whose etiology is not yet
fully understood (Shouval and Rufo, 2017). The two major
types of IBD are ulcerative colitis (UC) and Crohn’s disease
(CD). These two conditions share many clinical and pathological
characteristics and are often considered together. However,
they present different symptoms and clinical features, reflecting
differences in the site of inflammation and in the type of
immunological mechanisms involved in the pathogenesis that are
characteristic of each of them (Gecse and Vermeire, 2018).
Inflammatory bowel diseases are considered multifactorial
diseases triggered by an array of different factors, including
immunological and intestinal barrier dysfunction as well as
microorganisms (Nagao-Kitamoto et al., 2016; Bernstein and
Forbes, 2017; Lanis et al., 2017; Shouval and Rufo, 2017; Gecse
and Vermeire, 2018; Yu, 2018). Among these factors, the most
prominent are: (i) imbalance of luminal mucosal homeostasis
and induction of intestinal inflammation linked to environmental
stimuli in genetically susceptible subjects; (ii) altered balance
between regulatory mediators of inflammation, such as IFNγ
and TNFα, that contribute to an inappropriate and sustained
inflammatory response. Noteworthy, the high expression of
pro-inflammatory cytokines and the increase of inflammatory
cells can, in the long run, contribute to the formation of a
microenvironment that supports the growth and proliferation of
cancer cells and, for this reason, colorectal cancer (CRC) appears
as one of the most serious complications of IBD; and (iii) loss
of intestinal mucosal integrity. Consequently, intestinal dysbiosis
occurs. This phenomenon is caused by the alteration in the
composition of the intestinal microbiota due to exogenous (diet,
smoking, antibiotics) and endogenous (psycho-physical stress)
factors, Figure 1.
It is clear that IBDs have multiple etiopathogenic mechanisms.
This complexity in etiology and pathogenic mechanisms, along
with the need to design an optimal patient-customized therapy,
generates an urgent need for exploring new alternatives. Here, we
introduce the chaperonin Hsp60 as a candidate for investigation
toward elucidating the pathogenic mechanisms of IBDs.
The reasons to focus on Hsp60 as biomarker useful in
patient management and as a potential pathogenic agent in
IBD are varied, as follows: (1) Hsp60 can induce production
of pro-inflammatory cytokines (Sangiorgi et al., 2017; Cheong
et al., 2018; Sun et al., 2018; Swaroop et al., 2018); (2) its
quantities in UC mucosa vary in parallel with disease status,
high in relapse and low in remission (Rodolico et al., 2010;
Tomasello et al., 2011b); (3) its reported role in other conditions
with inflammatory component, for instance atherosclerosis
(Grundtman et al., 2011; Wick et al., 2014; Wick, 2016; Rahman
et al., 2017); (4) there is ample epitope sharing between
Hsp60s of various origins and human Hsp60 and other tissues
(including intestinal ones). This molecular mimicry (Bachmaier
and Penninger, 2005) elicits crossreactive antibodies reacting
not-only with the immunizing antigen (e.g., Hsp60 from a
bacterium infecting the intestinal or the genitourinary tract),
but also with human Hsp60 and intestinal antigens (Füst et al.,
2012). Autoimmunity due to molecular mimicry involving Hsp60
has been reported for various pathological conditions such as
myasthenia gravis (Cappello et al., 2010; Marino Gammazza et al.,
2012), Hashimoto’s thyroiditis (Marino Gammazza et al., 2014;
Tonello et al., 2015), chlamydial infections (Campanella et al.,
2009; Cappello et al., 2009), Guillain Barré syndrome (Loshaj-
Shala et al., 2015), and periodontitis (Rizzo et al., 2012; Buhlin
et al., 2015); and (5) despite all these revealing clues, research
on the possible direct role of Hsp60 in the pathogenesis of IBD
is not as abundant as it should be to make progress in disease
monitoring and treatment.
In this short review, we aim to gather the few reports available
on Hsp60 and IBDs and, thereby, provide a launching platform
for innovative research to answer two key questions: (a) Does
Hsp60 play a direct pathogenic role? and (b) If yes, What are the
molecular mechanisms involved and where do they occur in the
intestinal wall?
MOLECULAR CHAPERONES: ROLES IN
HEALTH AND DISEASE
Molecular chaperones are essential for cell differentiation, tissue
homeostasis, and organ remodeling in virtually all anatomical
districts, including the intestinal tract (Rodolico et al., 2010;
Tomasello et al., 2011b). They orchestrate the correct folding
of many proteins and protect cells from the deleterious
consequences of stress by preventing protein misfolding,
premature degradation, or aggregation (Macario et al., 2013).
The crucial role of molecular chaperones in intestinal tissues
homeostasis is illustrated by the fact that their dysregulation in
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FIGURE 1 | Diagram of the natural history of IBD from the standpoint of
Hsp60 and its most feared complication, colorectal cancer. (A) Normal colon
(or colon of an IBD patient in remission), showing the normal symbiotic flora
(top icons; circles of various colors indicate different species of microbes of
the normal, healthy microbiota) immersed in the mucous, both forming the
functional mucous-microbiota (MuMi) layer, and epithelium with individual cells
as rectangles (green) containing few Hsp60 molecules (blue hourglass).
(Continued)
FIGURE 1 | Continued
Also shown are immune system cells (star), e.g., macrophages and dendritic
cells, and a vessel (blood or lymphatic; undulating band with red borders) in
the lamina propria. The thick, orange vertical arrow pointing downward
indicates initiation or relapse of IBD, illustrated in (B). (B) Inflamed colon of an
IBD patient in relapse. The flora is altered (dysbiosis; while circles indicate
normal flora, see (A), the incomplete circles of different colors indicate various
microbes that are abnormal, not part of the healthy microbiota, and some may
be pathogenic by themselves), and epithelial cells are changed (yellow)
affected by the pathologic process with elevated levels of Hsp60, which may
be involved in the initiation of carcinogenesis by inhibiting the apoptosis of
epithelial cells with malignant DNA transformation, as represented by the two
epithelial cells in orange (dysplasia; extreme right). Hsp60 is elevated also in
immune system cells and is secreted into the extra-cellular space and/or
exposed on the surface and stimulates T lymphocytes (black circle with
quadrant missing) and secretion of pro-inflammatory cytokines (solid red
circles). Secreted Hsp60 can also reach the general circulation as indicated by
the hourglasses inside the lumen of the vessel. The thick vertical reddish
arrow pointing downward indicates malignant transformation, illustrated in the
(C). The green arrow to the right suggests the expected effect (i.e., the
reversal to a normal physiological situation) of IBD treatment aiming at
inhibiting/blocking the anti-apoptotic and pro-inflammatory effects of Hsp60
(i.e., negative chaperonotherapy, consisting in blocking the pathogenic action
of a chaperone). (C) Early (in situ) colon carcinoma developed on an IBD
patient. The main feature is the profound transformation of many epithelial
cells. Malignant cells are represented by reddish rectangles with altered nuclei,
while cells still undergoing transformation (dysplasia) are shown in orange, as
those shown in (B), extreme right. Transformed cells have also elevated levels
of Hsp60 and secrete the chaperonin into the extracellular space, mostly via
exosomes (double-bordered circles). The amount of Hsp60 reaching the
general circulation in exosomes or free increases considerably, and can be
used as a biomarker for patient follow-up and for monitoring response to
treatment. Note in the MuMi layer that the predominance of abnormal
microbes (incomplete circles) with regard to the normal microbes (circles) is
more marked than in (B).
intestinal epithelial cells (including absorptive, Paneth’s, goblet,
and entero-endocrine cells) drives colitis in experimental animals
and patients with IBD (Ma et al., 2017). Specifically Hsp60,
the focus of this review, plays a key role in the maintenance
of intestinal epithelial stemness and proliferation (Berger et al.,
2016), as we will discuss later.
Many chaperones are expressed in inflammation sites,
probably participating in tissue regeneration (Hightower et al.,
2000; Vitadello et al., 2010; Thanos et al., 2014). Also for this
reason, in principle we consider inflammation a physiological
phenomenon necessary for tissue repair through the proliferation
and differentiation of normal cells but, when inflammation
is either defective or excessive, it becomes pathogenic and
leads to disease.
A set of proteins belonging to the class of molecular
chaperones are heat shock proteins (Hsps), a group of proteins
highly conserved during the evolution. The term “Hsp” derives
from the observation that the concentration of these proteins
increases following exposure to thermal stress (Ritossa, 1996).
However, in the last decades it has been shown that Hsp levels
can also increase after various stimuli other than thermal stress
(Macario and Conway de Macario, 2005). They can be classified
into two categories (Macario et al., 2013): (a) constitutive Hsps,
are constitutively present inside the cell and act as molecular
chaperones to guarantee the correct folding of other proteins,
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and the translocation of the mature proteins through the cell
membranes, among other functions; and (b) inducible Hsps,
that are produced, sometimes in large quantities, under stress
conditions, whose primary role is to stabilize other proteins,
preventing their denaturation during stress, and other functions
unrelated to protein homeostasis.
Hsp chaperones typically reside in the various subcellular
compartments such as nucleus, endoplasmic reticulum,
microvesicles, and mitochondria (Macario and Conway de
Macario, 2005), but can also occur extracellularly. For example,
they can be secreted out of the cell via Golgi or in extracellular
vesicles (EVs), such as exosomes (Campanella et al., 2012).
Extracellular vesicles are important for cell to cell
communication and for this reason Hsps are now considered key
proteins in intercellular cross-talk (Caruso Bavisotto et al., 2017).
Once released, Hsps can act in two ways: (a) paracrine-like, when
their targets are located near the cells that have secreted them,
and (b) systemic (i.e., endocrine-like), when they reach their
targets through the bloodstream.
Hsps play also an important role in carcinogenesis as many
cancer-related proteins have been reported as Hsps clients (Rappa
et al., 2012). Therefore, during carcinogenesis Hsps work for
the tumor rather than for the host (chaperonopathy by mistake)
(Macario et al., 2013). Consequently, cancer treatments targeting
Hsps have been developed that can modulate various pathways
of cancer progression, including neoplastic growth, angiogenesis,
invasiveness, metastasis, and resistance to chemotherapy and
radiotherapy (Rappa et al., 2012).
The role of Hsps in the immune response has been the
focal point of a variety of studies (Macario et al., 2010). Hsps
receptors have been identified on antigen-presenting cells
(APCs) and a subset of T cells. It was hypothesized that Hsps
are an important element in the defense against damage due
to autoimmune mechanisms. Numerous studies have focused
on the role of Hsps both as an element of pathophysiology
in immune processes and as a potential therapeutic target.
Another interesting aspect of the interaction between Hsps
and immune system concerns the phenomenon of molecular
mimicry (Bachmaier and Penninger, 2005; Cappello et al.,
2009). This phenomenon is caused by a structural similarity
between Hsp molecules present in pathogenic bacteria and
human Hsps and other molecules. An immune response
to a foreign Hsp of bacterial origin could result in cross-
reaction against the host’s ortholog Hsp, generating an
autoimmune condition. This mechanism could be the basis
of sustained chronic inflammatory processes such as those that
occur in IBD.
CHAPERONINS, A UNIQUE CLASS OF
CHAPERONES
Hsps are grouped considering their molecular weight into six
groups: Super heavy Hsp, Hsp90, Hsp70, Hsp60 (chaperonins),
Hsp40, and small Hsp or sHsp (kDa: 100 or higher, 81–99,
65–80, 55–64, 35–54, and 34 or lower, respectively) (Macario
et al., 2013), and their nomenclature has been organized
(Kampinga et al., 2009). Hsp60 belongs to the group falling
within the 55–64 kDa range and has unique characteristics,
for instance, it can form very large macromolecular complexes
of about ∼ 1 MDa, and has been called “chaperonin”
(Hemmingsen et al., 1988).
Classically, there are two groups of chaperonins (Vilasi
et al., 2018), although a third group has recently been
proposed (Rowland and Robb, 2017). Hsp60 belongs to Group
I and it is classically considered a mitochondrial chaperone.
Group II is represented by TRiC (TCP-1 Ring Complex), also
called CCT (Chaperonin Containing TCP-1), and it works
in the cytosol.
Although Hsp60 was initially considered an
intramitochondrial protein, nowadays we know that it can
also occur beyond mitochondria, for instance in the cytosol, the
extracellular space, on the surface of normal and pathological
cells (such as cancer cells), and other locales (Merendino
et al., 2010). Its translocation to the extracellular medium is
possible during stress conditions, such as inflammation and
cancer (Figures 1B,C).
Hsp60 IN BOWEL PHYSIOLOGY AND
PATHOPHYSIOLOGY
Hsp60 is both constitutive and inducible. Under stress conditions
its levels increase considerably, accumulates in the cytosol
and can be secreted out of the cell via classic (Golgi’s)
and alternative (exosomal) pathways (Merendino et al., 2010;
Campanella et al., 2012).
Although Hsp60 can reside and function in a variety of
intra- and extra-cellular locales, its canonical location is the
mitochondrial matrix. Inside mitochondria, Hsp60 assists in the
folding of all mitochondrial proteins, including those of the
electron transfer chain for ATP production, thus playing a crucial
role in the maintenance of cellular and tissue (including the
intestinal tissue) physiology (Dencher et al., 2007; Takada et al.,
2010; Berger et al., 2016). Absence of Hsp60 in intestinal epithelial
cells causes the activation of the mitochondrial unfolded protein
response (mtUPR) with mitochondrial dysfunction, resulting in
loss of stemness and cell-proliferative capacity (Berger et al.,
2016). Moreover, mitochondrial dysfunction is associated with
paracrine release of WNT-related signals and hyperproliferation
of residual stem cells that have escaped Hsp60 deletion (Berger
et al., 2016). Hence, Hsp60 is crucial in the control of the epithelial
stem cell niche of the bowel.
Upregulation of Hsp60 is a part of the exaggerated
inflammatory response in some pathological conditions such
as bronchitis (Cappello et al., 2011; Sangiorgi et al., 2017),
keratoconjunctivitis (Leonardi et al., 2016), hepatitis (Barone
et al., 2016), thyroiditis (Marino Gammazza et al., 2014),
periodontitis (Rizzo et al., 2012), and IBD (Rodolico et al., 2010)
(for details and illustrative images see Data Availability Statement
just prior to the References list). We found Hsp60 in cells typical
of inflammation in lamina propria in histological samples of IBDs
but not in normal controls (Rodolico et al., 2010). This prompted
us to hypothesize that this chaperonin could be implicated in
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the activation of the immune system leading to inflammation,
particularly when alterations of the MuMi layer are present.
Subsequently, we reported that after treatment of patients
with IBD with 5-aminosalicylic acid, alone or in combination
with probiotics, amelioration of symptoms was associated
with reduction of both inflammation and Hsp60. Interestingly,
the levels of Hsp60 positively correlated with those of CD68-
positive cells, and double immunofluorescence showed a
high index of colocalization of the chaperonin and CD68
in lamina propria (Tomasello et al., 2011a). A correlation
between gut microbiota imbalance and chaperoning system
malfunction in IBD has also been suggested (Bellavia
et al., 2013), as supported by data showing that probiotics
supplementation reduce Hsp60 levels as well as its post-
translational modifications (Barone et al., 2016); these
modifications may be related to its secretion outside cells
(Campanella et al., 2016), not only in its free, soluble form but
also in the membrane of exosomes.
In agreement with these findings, antibodies against Hsp60
were found in patients with IBD (Elsaghier et al., 1992).
These studies are worth expanding because of the potential
implications of the findings in the development of therapeutic
means for IBD.
Strong positivity staining for Hsp60 in mononuclear cells of
the intestinal mucosa of patients with IBDs has been reported
(Peetermans et al., 1995). Double staining for B7 and Hsp60
showed that Hsp60 was present in B7-positive cells, thus
supporting the hypothesis that Hsp60 may play a role in the
initiation and/or maintenance of the inflammatory process.
Severe intestinal pathology was induced by the adoptive transfer
of an Hsp60-specific CD8+ T-lymphocyte clone pre-activated by
bacterial Hsp60, into TCR−/− or SCID mice (Steinhoff et al.,
1999). Colitis induction required the presentation of Hsp60 on
MHC class I and depended on a functional role of TNF-α. In
contrast to the findings obtained in other experimental models,
inflammation did not depend on the presence of the resident
bacterial flora in the MuMi layer. Thus, the results indicated
that autoimmune Hsp60 CD8+ T cells, that were reactive to
cellular Hsp60, mediated the pathogenesis of this very severe
colitis. Furthermore, anti-inflammatory effects of prozumab, a
humanized anti-HSP monoclonal antibody able to bind Hsp60,
occurred in murine inflammatory colitis via: (a) induction of
IL-10 secretion from naive human peripheral blood mononuclear
cells; and (b) suppression of secretion of IFN-γ and IL-6 from
anti-CD3-activated cells (Ulmansky et al., 2015).
Hsp60, in contrast to other molecular chaperones, is
increased intracellularly in epithelial cells during early stages
of colon carcinogenesis, i.e., intestinal adenomatous polyps
with dysplasia (Cappello et al., 2003) (Figure 1B), a condition
in which an alteration of the MuMi layer homeostasis is
present (Kang and Martin, 2017). This information has
been confirmed in other studies (Cappello et al., 2005;
Campanella et al., 2015; Rappa et al., 2016) that correlated
also Hsp60 levels to peritumoral inflammation and disease
clinical course.
In tumor cells, Hsp60 binds pro-caspase 3, thus blocking
apoptosis (Campanella et al., 2008). Hsp60 interacts also with
cyclophilin D (Cyp-D), thus preventing Cyp-D dependent
tumor-cell death through the formation of a complex with Hsp90
and tumor necrosis factor receptor-associated protein-1 (Ghosh
et al., 2010). It has also been shown that Hsp60 plays a role
in tumor cell survival through the activation of the NF-KB
pathway (Chun et al., 2010). Hsp60 interacts directly with IKKα/β
through the activation-dependent serine phosphorylation in a
chaperone-independent manner to promote the TNF-α mediated
activation of the IKKβ/NF-κB survival pathway (Chun et al.,
2010). Finally, in tumor cells, Hsp60 is prone to undergo
post-translational modifications that facilitate its secretion in the
peritumoral microenvironment with pro-tumoral effects being
likely (Gorska et al., 2013; Campanella et al., 2016; Marino
Gammazza et al., 2017).
The data discussed in the preceding paragraphs implicate
Hsp60 in the mechanisms causing various types of diseases,
including IBD. Therefore, the need of more research becomes
acutely apparent; research that should aim, for instance, at
elucidating the molecular aspects of the Hsp60’s pathogenicity
directly in the intestinal tissue. The results should help in
the discovering of novel and efficacious therapeutic agents.
In this regard, it is of interest to report that Hsp60 can be
negatively modulated by specific inhibitors, both natural
products and synthetic compounds (Pace et al., 2013; Cappello
et al., 2014; Meng et al., 2018). These potential therapeutic agents,
e.g., mizoribine, epolactaene, myrtucommulone, stephacidin
B, avrainvillamide, o-carboranylphenoxyacetanilides, and
gold (III) porphyrins were identified by chemoproteomics,
and constitute the subject matter of another line of
research that also deserves consideration in the efforts
to cure IBD.
CONCLUSION AND PERSPECTIVES
Inflammatory bowel disease has a multifactorial
etiopathogenesis. The molecular chaperone Hsp60 is emerging
as a prominent player not only in the mechanisms of disease
but also because of its potential as biomarker useful for
diagnosis and patient monitoring and as therapeutic target.
Normally, Hsp60 is one of the most important proteins
for cell survival, proliferation, and differentiation. This
chaperonin plays a key role in the maintenance of protein
homeostasis inside mitochondria, including in the intestine.
It also functions in many other processes unrelated to protein
homeostasis beyond mitochondria. However, Hsp60 can
be pathogenic. Of interest for this article are the potential
roles of Hsp60 in IBD pathogenesis and complications,
including carcinogenesis. Hsp60 has been implicated in
IBD pathogenesis, in the initiation and/or maintenance of
the inflammatory process. Furthermore, it is most likely
involved in the process of bowel carcinogenesis in patients
with IBD. Colon rectal cancer is one of the most serious
complications of IBD, and Hsp60 seems to be involved in
carcinogenesis. With this concept in mind, efforts should be
made to elucidate whether or not Hsp60 plays a direct pathogenic
role in IBD. If, indeed, Hsp60 does play a pathogenic role in
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IBD, research should be done to dissect the pertinent molecular
mechanisms and to determine where exactly in the intestinal wall
they occur. The results should help in the development of novel
therapies targeting Hsp60.
In summary, the data discussed in this review support
the notion that Hsp60 is worth investigating as a potential
etiopathogenic factor in IBD. It is hoped that the results will
provide the basis for IBD treatment focusing on the chaperonin
to alleviate inflammation and prevent one of its most feared
complications, colon cancer.
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